Ultragenyx Pharmaceutical | RARE - Sales Revenues

Stock Price
24.04
Daily Change
-0.49 -2.00%
Monthly
24.56%
Yearly
-38.33%
Q2 Forecast
23.58

Ultragenyx Pharmaceutical reported $207M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Kyowa Hakko Kirin JPY 147.38B 28.58B Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
Moderna USD 678M 342M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xoma USD 25K 5M Sep/2024